Skip to main content
. 2021 Nov 25;13(23):5937. doi: 10.3390/cancers13235937

Figure 1.

Figure 1

Orai3 expression is inversely associated with the mean survival time of pancreatic cancer patients. (A) Orai3 expression analysis in GEPIA (Gene Expression Profiling Interactive Analysis) database having 179 pancreatic tumor samples (T) and 171 normal pancreas samples (N). Here “*” indicates that Orai3 expression is significantly higher in pancreatic tumor samples in comparison to normal pancreas samples. (B) Pancreatic cancer patients’ survival analysis in GEPIA wherein blue trace corresponds to low Orai3 expression (n = 89 patients) and red trace represents high Orai3 expression (n = 89 patients) clearly suggesting that higher Orai3 expression is associated with less patient survival time. (C) Pancreatic cancer patients’ survival analysis in “The Human Protein Atlas” database where blue trace corresponds to low Orai3 expression (n = 124 patients) and red trace represents high Orai3 expression (n = 52 patients) demonstrates that higher Orai3 levels are associated with poor prognosis and leads to decrease in patients’ survival time. (D) Western blot analysis for examining Orai3 protein levels in well-established pancreatic cancer cell lines and transformed “normal” pancreatic cells. (E) ImageJ based densitometric analysis of Orai3 expression in pancreatic cancer cell lines suggest differential Orai3 expression profile (n = 4).